PT  - JOURNAL ARTICLE
AU  - NOBUYOSHI FUKUMITSU
AU  - HITOSHI ISHIKAWA
AU  - TAKESHI ARIMURA
AU  - HITOSHI WADA
AU  - TOMOAKI OKIMOTO
AU  - YOSHITAKA SATO
AU  - HIROMITSU IWATA
AU  - SHOSEI SHIMIZU
AU  - HIDEYUKI SAKURAI
TI  - Proton Therapy for Primary Renal Cell Carcinoma: The First Nationwide Retrospective Study in Japan
AID  - 10.21873/invivo.12116
DP  - 2020 Sep 01
TA  - In Vivo
PG  - 2883--2889
VI  - 34
IP  - 5
4099  - http://iv.iiarjournals.org/content/34/5/2883.short
4100  - http://iv.iiarjournals.org/content/34/5/2883.full
SO  - In Vivo2020 Sep 01; 34
AB  - Background/Aim: This multi-institutional study aimed to investigate the efficacy and feasibility of proton beam therapy (PBT) for renal cell carcinoma (RCC) in Japan. Patients and Methods: The survival, local control, and toxicities in 22 RCC patients treated between 2001 and 2016 at 6 Japanese PBT institutes were analyzed. Results: The 22 patients comprised 20 men and had a median age of 67 (range=42-88) years. The total irradiation dose was 60-79.6 Gy (relative biological effectiveness). Over a median follow-up of 37 months, the 3-year overall and disease-specific survival rates were 95% and 100%, respectively, and no recurrence occurred. No patient experienced grade 3 or higher adverse events. The serum blood urea nitrogen (p=0.25) and creatinine levels (p=0.95) were not significantly affected, although the mean estimated glomerular filtration rate was reduced by 7.1±11.2 ml/min/1.73 m2. Conclusion: Despite the small number of patients, high-dose PBT can control RCC while maintaining their renal function with high probability, and could be and alternative curative therapy especially for inoperable patients.